with
-
Recon
Implanet Initiates a Prospective and Multicenter Clinical Study in Partnership with TFS International
BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible) (Paris:IMPL), a medical technology company specialized in vertebral…
Read More »